CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer

Cancer Research

Volumn 64, Issue 17, 2004, Pages 5956-5962

  Enokida, Hideki ^a,d   Shiina, Hiroaki ^a,b   Igawa, Mikio ^b   Ogishima, Tatsuya ^a   Kawakami, Toshifumi ^a   Bassett, William W ^a   Anast, Jason W ^a   Li, Long Cheng ^a   Urakami, Shinji ^b   Terashima, Masaharu ^b   Verma, Mukesh ^c   Kawahara, Motoshi ^d   Nakagawa, Masayuki ^d   Kane, Christopher J ^a   Carroll, Peter R ^a   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SHIMANE UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; COMPLEMENTARY DNA; DNA; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MDR 1 GENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE;

AGED; AGED, 80 AND OVER; APOPTOSIS; AZACITIDINE; BASE SEQUENCE; CELL DIVISION; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, MDR; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 4344633280     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0081     Document Type: Article

References (37)

1. Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000;163: 1802-7.
2. Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153: 1020-5.
3. Oh WK. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J Urol 2003;170:S28-32; discussion S33-4.
4. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-Glycoprotein: from genomics to mechanism. Oncogene 2003;22:7468-85.
5. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990:265:506-14.
6. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996;27:1283-91.
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
8. El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation Mol Cell Biol 2002;22:1844-57.
9. Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002;8:2217-24.
10. Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate- resistant human breast cancer cells. J Biol Chem 2001;276:39990-40000.
11. Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000;6:4618-27.
12. Takanishi K, Miyazaki M, Ohtsuka M, Nakajima N. Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma. Oncology 1997;54:231-7.
13. Scotlandi K, Manara MC, Serra M, et al. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene 1999;18:739-46.
14. Kawai K, Sakurai M, Sakai T, et al. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 2000;150:147-53.
15. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, et al. Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001;165:130-5.
16. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 1998;4:1393-403.
17. nd ed. Tokyo, Japan: Kanahara-Shuppan Co.; 1992.
18. Shigeno K, Igawa M, Shiina H, Wada H, Yoneda T. The role of colour Doppler ultrasonography in detecting prostate cancer. BJU Int 2000;86:229-33.
19. Narayan P, Dahiya R. Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol 1992;148:1600-4.
20. Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997; 72:762-7.
21. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987;262: 17432-6.
22. Cornwell MM, Smith DE. SP1 activates the MDRI promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 1993;268: 19505-11.
23. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
24. Watanabe I, Toyoda M, Okuda J, et al. Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods. Jpn J Cancer Res 1999;90:188-93.
25. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (Bethesda) 2001;93:1747-52.
26. Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999;9:349-357.
27. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003;9:827-36.
28. Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer (Phila.) 1994;74:2908-17.
29. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.
30. Worm J, Bartkova J, Kirkin AF, et al. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 2000;19:5111-5.
31. Bao JJ, Lee BP, Stephens LC, et al. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis B virus transgenic mice lacking MDR1a-encoded P-glycoprotein. Mol Carcinog 2000;29:103-11.
32. Sanchez-Carbayo M, Belbin TJ, Scotlandi K, et al. Expression profiling of osteosarcoma cells transfected with MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and tumor suppression-related genes. Lab Investig 2003;83:507-17.
33. Li D, Jang SH, Kim J, Wientjes MG, Au JL. Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res 2003;20:45-50.
34. Gan Y, Wientjes MG, Au JL. Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin Cancer Res 1998;4:2949-55.
35. Karwatsky J, Lincoln MC, Georges E. A mechanism for P-glycoprotein- mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 2003;42:12163-73.
36. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95: 281-6.
37. Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000;164:1465-72.